AFIB · As filed with the SEC
Acutus Medical income statement, by quarter
The statement as Acutus Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 |
|---|---|---|---|---|
| Revenue | 7,130† | 5,266 | 4,127 | 3,625 |
| Cost of products sold | 6,125† | 4,894 | 4,470 | 3,655 |
| Gross profit (loss) | 1,005† | 372 | (343) | (30) |
| Operating expenses (income): | ||||
| Research and development | 0† | 0 | 0 | 0 |
| Selling, general and administrative | 2,556† | 2,318 | 2,225 | 3,337 |
| Change in fair value of contingent consideration | 0† | 0 | 0 | 0 |
| Gain on sale of business | (2,718)† | (2,435) | (2,869) | (2,792) |
| Total operating expenses | 1,286† | (117) | (644) | 545 |
| Loss from operations | (281)† | 489 | 301 | (575) |
| Other income (expense): | ||||
| Change in fair value of warrant liability | 108† | (174) | 564 | (283) |
| Interest income | — | — | — | 281 |
| Interest expense | — | — | — | (1,478) |
| Interest income | 122† | 153 | 207 | — |
| Interest expense | (1,374)† | (1,395) | (1,510) | — |
| Other revenue | — | 111 | 76 | — |
| Total other expense, net | (1,030)† | (1,305) | (663) | (1,480) |
| Loss from continuing operations before income taxes | (1,311)† | (816) | (362) | (2,055) |
| Income tax expense | — | — | — | 0 |
| Net loss from continuing operations | (1,311)† | (816) | (362) | (2,055) |
| Discontinued operations: | ||||
| Loss from discontinued operations before income taxes | (93)† | (4,791) | (552) | 445 |
| Income tax expense - discontinued operations | 2† | 0 | 0 | (10) |
| Loss from discontinued operations | (95)† | (4,791) | (552) | 435 |
| Net loss | (1,406)† | (5,607) | (914) | (1,620) |
| Other comprehensive income (loss): | ||||
| Unrealized gain on marketable securities | 0† | 0 | 0 | 0 |
| Foreign currency translation adjustment | 113† | (15) | 0 | 0 |
| Comprehensive loss | (1,293)† | (5,622) | (914) | (1,620) |
| Net loss per share, basic and diluted: | ||||
| Loss from continuing operations, basic (in dollars per share) | — | (0.03) | (0.01) | (0.07) |
| Loss from discontinued operations, basic (in dollars per share) | — | (0.16) | (0.02) | 0.01 |
| Net loss per common share, basic (in dollars per share) | — | (0.19) | (0.03) | (0.06) |
| Net earnings (loss) per share, diluted: | ||||
| Loss from continuing operations, (in dollars per share) | — | (0.03) | (0.01) | (0.07) |
| Loss from discontinued operations , diluted (in dollars per share) | — | (0.16) | (0.02) | 0.01 |
| Net loss per common share, diluted (in dollars per share) | — | (0.19) | (0.03) | (0.06) |
| Weighted average number of common shares outstanding, basic (in shares) | — | 29,799,241 | 29,721,542 | 29,693,926 |
| Weighted average number of common shares outstanding, diluted- continuing operations (in shares) | — | 29,799,241 | 29,721,542 | 29,693,926 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.